Subacute toxicity studies of ebrotidine -[[[2-(diaminomethylene)amino]
-4-thiazolyl]methyl] ethyl]amino]methylene]-4-bromo-benzenesulfonamide
, CAS 100981-43-9, FI-3542) were performed in Sprague-Dawley rats and
Beagle dogs. Both animal species were administered with the same dose
levels (50, 200 and 500 mg/kg) for 4 and 7 weeks, respectively. In a p
revious 4-week subacute toxicity study in the rat, ranitidine and cime
tidine at 500 mg/kg were used as reference drugs. The results indicate
d that ebrotidine was well tolerated at 50 mg/kg, while there were dos
e-related effects at 200 and 500 mg/kg. Probably due to its pharmacoki
netics, ebrotidine was more toxic in dogs than in rats, since the most
severe effects were the death or sacrifice in extremis of two dogs fr
om the high dose group which had undergone rectal prolapse, while no d
eaths occurred in the rats. The changes that were very likely related
to treatment (500 mg/kg) were a lower weight in both species, a slight
decrease of hematocrit and red blood cells in rats, single increments
of transaminases, alkaline phosphatase and lactate dehydrogenase in d
ogs (some animals of the 200 mg/kg dose group were also affected) and
a higher liver weight. These effects with a few exceptions were found
to be common to cimetidine and ranitidine.